An interventional study of Test Spectacle Lens & Contact Lens and Control Spectacle Lens & Contact Lens in Myopia, sponsored by CooperVision International Limited (CVIL). Not yet recruiting at 2 sites in 2 countries. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by CooperVision International Limited (CVIL) (part of CooperCompanies) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Myopia by CooperCompanies — 7 open to participants now, 9 under way, none of them phase 3. Myopia · CooperCompanies.
Among the 117 studies in Myopia by CooperCompanies, this one is the 45th largest by planned enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2026, is one of 116 with no phase, and was the 115th registered.
1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →7 of the 117 studies in Myopia by CooperCompanies are open now, in 6 countries. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in United States
Ages 40+
CooperVision International Limited (CVIL) · Sites in United States, Spain
Ages 7–35
CooperVision International Limited (CVIL) · Sites in China
Ages 8–10
CooperVision International Limited (CVIL) · Sites in China
Ages 8+ · Healthy volunteers
CooperVision International Limited (CVIL) · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 11 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2026.
This study's planned enrollment of 58 is below the median of 79 across 926 interventional studies indexed under Myopia.
Median enrollment 50 across the 116 interventional studies, 53 across the 1 observational. Of the 106 that completed or were terminated, 94 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CooperVision International Limited (CVIL), one of the names counted as CooperCompanies. Under that name alone:
CooperVision International Limited (CVIL) is the lead sponsor of 139 studies on the registry; 7 are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 66 (89%) have results posted.
4 of the studies in Myopia by CooperCompanies that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07940426CooperVision International Limited (CVIL)Title: Clinical Performance and Outcomes After Sphere Lens Transition | 2027-02 |
| NCT07898995CooperVision International Limited (CVIL)Clinical Performance and Outcomes After Toric Lens Transition | 2027-02 |
| NCT07829419CooperVision International Limited (CVIL)Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens Wearers | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 117 studies in Myopia by CooperCompanies, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Effect of alternating contact lenses and spectacles for myopia control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will wear Test Spectacle Lens \& Contact Lenses
Device: Test Spectacle Lens & Contact Lens
Participants will wear Control Spectacle Lens \& Contact Lenses
Device: Control Spectacle Lens & Contact Lens
Participants will wear contact lenses for a target of 10 hours a day, 5 days per week and test spectacle lenses for remaining waking hours.
Participants will wear contact lenses for a target of 10 hours a day, 5 days per week and control spectacle lenses for remaining waking hours.
Change in axial length (AXL, mm) over 12 months
Time frame: Over 12 months
Start is estimated for Dec 2026; primary completion for Feb 2028, 14 months later.
Of 234 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 14 months is above that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CooperVision International Limited (CVIL) →